GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mega Lifesciences PCL (BKK:MEGA) » Definitions » Scaled Net Operating Assets

Mega Lifesciences PCL (BKK:MEGA) Scaled Net Operating Assets : 0.48 (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Mega Lifesciences PCL Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Mega Lifesciences PCL's operating assets for the quarter that ended in Dec. 2024 was ฿10,397 Mil. Mega Lifesciences PCL's operating liabilities for the quarter that ended in Dec. 2024 was ฿3,842 Mil. Mega Lifesciences PCL's Total Assets for the quarter that ended in Sep. 2024 was ฿13,533 Mil. Therefore, Mega Lifesciences PCL's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2024 was 0.48.


Mega Lifesciences PCL Scaled Net Operating Assets Historical Data

The historical data trend for Mega Lifesciences PCL's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Lifesciences PCL Scaled Net Operating Assets Chart

Mega Lifesciences PCL Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 0.51 0.48 0.47 0.46

Mega Lifesciences PCL Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.49 0.45 0.45 0.48

Competitive Comparison of Mega Lifesciences PCL's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Mega Lifesciences PCL's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mega Lifesciences PCL's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mega Lifesciences PCL's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Mega Lifesciences PCL's Scaled Net Operating Assets falls into.


;
;

Mega Lifesciences PCL Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Mega Lifesciences PCL's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: Dec. 2023 )
=(10397.105-3842.056)/14114.858
=0.46

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=14210.134 - 3813.029
=10397.105

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=4333.299 - 139.826 - 351.417
=3842.056

Mega Lifesciences PCL's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2024 )
=(Operating Assets (Q: Dec. 2024 )-Operating Liabilities (Q: Dec. 2024 ))/Total Assets (Q: Sep. 2024 )
=(10397.105-3842.056)/13532.761
=0.48

where

Operating Assets(Q: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=14210.134 - 3813.029
=10397.105

Operating Liabilities(Q: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=4333.299 - 139.826 - 351.417
=3842.056

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mega Lifesciences PCL Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Mega Lifesciences PCL's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Mega Lifesciences PCL Business Description

Traded in Other Exchanges
Address
Debaratna Road, 909, Ample Tower, 9th Floor, Bangna Nuea, Bangna, Bangkok, THA, 10260
Mega Lifesciences PCL manufactures and sells through independent distributors of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods as well as provides distribution services relating to such products. The company's product portfolio consists of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. Its segments include Brands in which goods are manufactured and sold under brands owned by the group; Distribution in which the group provides logistical and marketing services for goods trading purposes and sale of goods manufactured by third parties; and OEM.

Mega Lifesciences PCL Headlines

No Headlines